T‐cell antibody induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Polyclonal T‐cell antibody showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Monoclonal antibody showed no clear difference in mortality Mortality at latest compared with polyclonal antibody (low certainty).
Polyclonal T‐cell antibody induction showed no clear difference in mortality compared with interleukin‐2 receptor antagonist induction (moderate certainty).
T‐cell antibody induction showed no clear difference in mortality Mortality at latest compared with corticosteroid induction (low certainty).
T‐cell antibody induction may leads to lower mortality Mortality at latest compared with placebo/no intervention (low certainty).
IL‐2 receptor antagonist induction showed no clear difference in mortality compared with no antibody induction (moderate certainty).
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with polyclonal antibody induction (low certainty).
Palivizumab showed no clear difference in all‐cause mortality compared with placebo (moderate certainty).
Palivizumab showed no clear difference in all‐cause mortality compared with motavizumab (moderate certainty).
The intervention showed no clear difference in mortality Mortality at latest (low certainty).
Interleukin‐2 RA showed no clear difference in mortality Mortality at latest compared with no induction (low certainty).
Dinutuximab‐containing immunotherapy probably leads to lower overall survival (reported as mortality) compared with standard therapy (moderate certainty).
The review found no eligible studies for this question.
Dinutuximab‐containing immunotherapy probably leads to lower event‐free survival (reported as relapse, progressive disease,… compared with standard therapy (moderate certainty).